<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04634708</url>
  </required_header>
  <id_info>
    <org_study_id>E-20-330</org_study_id>
    <nct_id>NCT04634708</nct_id>
  </id_info>
  <brief_title>The Use of the EXCOR Active Driving Unit for Mobilization of Pediatric Patients With Ventricular Assist Device Support</brief_title>
  <acronym>E-Motion</acronym>
  <official_title>The Use of the EXCOR Active Driving Unit for Mobilization of Pediatric Patients With Ventricular Assist Device Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Berlin Heart GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Berlin Heart GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to evaluate the performance of the Berlin Heart&#xD;
      EXCOR Active driving unit while being used with the approved EXCOR ventricular assist device&#xD;
      system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has a prospective, multicenter, international, single arm, observational design.&#xD;
&#xD;
      Study enrollment is expected to take 18 months and subjects will be followed until they reach&#xD;
      an outcome or for 45 days on the EXCOR Active driving unit. The overall study duration is&#xD;
      expected to be approximately 20 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>EXCOR Active device performance</measure>
    <time_frame>52 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful patient outcome rates</measure>
    <time_frame>Whenever it happens or 52 days</time_frame>
    <description>Successful outcome is defined as:&#xD;
survival to transplant, or&#xD;
survival to recovery/successful weaning, or&#xD;
survival on EXCOR Pediatric at 45 days post-switch to EXCOR Active.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety of the device</measure>
    <time_frame>52 days</time_frame>
    <description>Adverse Events and Adverse Device Effects&#xD;
Serious Adverse Events and Serious Adverse Device Effects</description>
  </other_outcome>
  <other_outcome>
    <measure>Mobility</measure>
    <time_frame>52 days</time_frame>
    <description>The mobility will be assessed with a patient diary.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life of the Patient and Family</measure>
    <time_frame>52 days</time_frame>
    <description>The QoL will be assessed with questionnaires.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Heart Failure</condition>
  <condition>Cardiomyopathies</condition>
  <condition>Ventricular Dysfunction</condition>
  <condition>Heart Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Pediatric patients on EXCOR VAD support</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention due to observational design</description>
    <arm_group_label>Pediatric patients on EXCOR VAD support</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Twenty patients supported with the EXCOR® VAD. Patients must meet the eligibility criteria&#xD;
        as specified and must not meet the exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pediatric patients meeting all indications as specified in the current version of the&#xD;
             instructions for use (IFU) of the EXCOR® Active system,&#xD;
&#xD;
          -  Age &lt; 18 years,&#xD;
&#xD;
          -  Patient and legal guardian has consented via signature on the study informed consent&#xD;
             form,&#xD;
&#xD;
          -  Patient is able to get mobilized according to hospital standard and is currently&#xD;
             supported with the Ikus driving unit. The decision if a patient is able to get&#xD;
             mobilized is at the discretion of the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has any contraindication as specified in the current version of the IFU of the&#xD;
             EXCOR® Active system,&#xD;
&#xD;
          -  Patient and/or legal representative has not given written consent to participate in&#xD;
             the study (non-consent),&#xD;
&#xD;
          -  Females of childbearing age who are not on contraceptives or surgically sterile or who&#xD;
             are pregnant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas Schöndorf, Dr. Dr. PD</last_name>
    <phone>+49-30 81872767</phone>
    <email>thomas.schoendorf.@berlinheart.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nadia Sinner</last_name>
    <phone>+49-30 81872687</phone>
    <email>nadia.sinner@berlinheart.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EXCOR Ventricular Assist Device</keyword>
  <keyword>EXCOR Active</keyword>
  <keyword>Mobilization</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

